in vivo News and Research

RSS

BioTime subsidiary releases version 1.5 of LifeMap Discovery

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the release of LifeMap Discovery version 1.5. LifeMap Discovery is a state-of-the-art roadmap of embryonic development and stem cell biology.

18 Jan 2014

Professor wins NSF CAREER grant to develop 5-D in vivo image of atherosclerotic plaques

Currently, the medical community has limited ability in clinically assessing blockages called atherosclerotic plaques in the human body. These dangerous blockages that can lead to heart attacks and strokes are not easily diagnosed due to "the lack of noninvasive imaging techniques to accurately model atherosclerotic plaques in vivo," said Guohua Cao, assistant professor of biomedical engineering at Virginia Tech.

17 Jan 2014

Researchers develop automated venipuncture device that automates phlebotomy procedure

A new medical device has been developed that will provide phlebotomists and clinicians with a technology to enable blood drawing accuracy at first stick. This is particularly important considering the diverse patient demographic each with various levels of difficult venous access.

10 Jan 2014

T2HemoStat detection of novel clot behavior could direct therapeutic choices for stroke, heart attack victims

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that scientists from the University of Pennsylvania and T2 Biosystems have published a paper in Blood describing novel clot structure biology detected while testing T2 Bio's T2HemoStat-.

10 Jan 2014

Montreal researchers identifies two specific key players in growth of GBM

Glioblastoma (GBM) is the most common and deadly form of primary malignant brain cancer accounting for approximately 15% of all brain tumours and occurring mostly in adults between the ages of 45 and 70.

9 Jan 2014

Study sheds light on the biological underpinnings of obesity

A new neuroscience study sheds light on the biological underpinnings of obesity. The in vivo study, published in the January 8 issue of the Journal of Neuroscience, reveals how a protein in the brain helps regulate food intake and body weight. The findings reveal a potential new avenue for the treatment of obesity and may help explain why medications that are prescribed for epilepsy and other conditions that interfere with this protein, such as gabapentin and pregabalin, can cause weight gain.

7 Jan 2014

Research confirms superior antitumor activity of novel anticancer agent FL118

A team led by Fengzhi Li, PhD, of Roswell Park Cancer Institute has reported significant new findings regarding the chemical structure of the novel anticancer agent FL118. The research, which included comparative analysis of the agent and several similar compounds, confirms the broad, superior antitumor activity of FL118 and suggests promising directions for further studies.

2 Jan 2014

Invivo Therapeutics receives FDA conditional approval to advance its first clinical trial

InVivo Therapeutics Holdings Corp. (NVIV) announced today that it has received conditional approval from the Food and Drug Administration for proposed changes to the protocol and supporting documents for the safety trial of its first investigational product, a degradable polymer scaffold for spinal cord injury.

27 Dec 2013

Manipulating epigenetic mechanism may promote cell death in pediatric brain cancer

Researchers at the Federal University of Rio Grande do Sul, the university hospital (Hospital de Cl-nicas de Porto Alegre, HCPA) and the Children's Cancer Institute (Instituto do C-ncer Infantil do Rio Grande do Sul, ICI-RS) in Porto Alegre, Brazil, have shown that manipulating an epigenetic mechanism, which regulates gene expression, may promote cell death and favor maturation towards less malignant-prone phenotypes in pediatric brain cancer cell lines.

22 Dec 2013

Study finds milk serves as protective carrier of bioactive molecules

Polyphenols found in tea manifest anti-cancer effects but their use is limited by poor bioavailability and disagreeable taste. A new study in the Journal of Dairy Science- finds that when epigallocatechin gallate (EGCG), the major extractable polyphenol in green tea and the most biologically active, when diluted in skim milk or other milk complexes remains bioactive and continues to reduce colon cancer cell proliferation in culture at concentrations higher than 0.03 mg of EGCG/mL.

20 Dec 2013

NUS scientists open possible new route for treatment of spinal muscular atrophy

A recent study led by scientists from the National University of Singapore (NUS) opens a possible new route for treatment of Spinal Muscular Atrophy (SMA), a devastating disease that is the most common genetic cause of infant death and also affects young adults.

18 Dec 2013

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia, was presented in a poster at the Annual Meeting of the American Society of Hematology, which took place on December 7-10, 2013.

17 Dec 2013

Nature Medicine selects CNIO study as most important discovery in regenerative medicine

The prestigious journal Nature Medicine has taken a look at the year and chosen one of the Spanish National Cancer Research Centre's (CNIO) studies as the most important in the stem cell category for its special December edition.

13 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

The need for biosimulation is primarily to do with the very high attrition rate in drug development and especially in the development of drugs for the central nervous system.

10 Dec 2013

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge.

10 Dec 2013

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data of selective HDAC6 inhibitor, ricolinostat (ACY-1215), in models of lymphoma were presented today in an oral presentation by Dr. Jennifer Amengual, Assistant Professor of Medicine & Experimental Therapeutics, Columbia University Medical Center.

10 Dec 2013

UC Santa Barbara professor finds method for measuring cellular forces that shape tissues, organs

Like tiny construction workers, cells sculpt embryonic tissues and organs in 3D space. This task is complicated and requires constant communication between cells to coordinate their actions and generate the forces that will shape their environment into complex tissue morphologies.

10 Dec 2013

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Repetitive transcranial magnetic stimulation uses a non-invasive and relatively painless tool to stimulate the human brain in vivo using very strong, pulsed magnetic fields. It is also used to explore and elucidate neocortical functions and treat neuropsychiatric disorders.

9 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

in vivo News and Research

BioTime subsidiary releases version 1.5 of LifeMap Discovery

Professor wins NSF CAREER grant to develop 5-D in vivo image of atherosclerotic plaques

Researchers develop automated venipuncture device that automates phlebotomy procedure

T2HemoStat detection of novel clot behavior could direct therapeutic choices for stroke, heart attack victims

Montreal researchers identifies two specific key players in growth of GBM

Study sheds light on the biological underpinnings of obesity

Research confirms superior antitumor activity of novel anticancer agent FL118

Invivo Therapeutics receives FDA conditional approval to advance its first clinical trial

Manipulating epigenetic mechanism may promote cell death in pediatric brain cancer

Study finds milk serves as protective carrier of bioactive molecules

NUS scientists open possible new route for treatment of spinal muscular atrophy

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Nature Medicine selects CNIO study as most important discovery in regenerative medicine

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

UC Santa Barbara professor finds method for measuring cellular forces that shape tissues, organs

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News